Ipsen S.A.
IPN.PADrugs in Pipeline
8
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Smecta (Diosmectite), duration of treatment - 7 days
Diarrhoea
IPN10200
Moderate to Severe Glabellar Lines
Elafibranor
Primary Biliary Cholangitis (PBC)
Lanreotide autogel
Gastroenteropancreatic Neuroendocrine Tumor
lanreotide (Autogel formulation)
Diarrhea
Odevixibat
Alagille Syndrome
Botulinum toxin type A
Cervical Dystonia
Lanreotide autogel 120 mg
Pancreatic Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Smecta (Diosmectite), duration of treatment - 7 days | Phase 3 | Diarrhoea | - | - |
IPN10200 | Phase 3 | Moderate to Severe Glabellar Lines | - | - |
Elafibranor | Phase 3 | Primary Biliary Cholangitis (PBC) | - | - |
Lanreotide autogel | Phase 3 | Gastroenteropancreatic Neuroendocrine Tumor | - | - |
lanreotide (Autogel formulation) | Phase 3 | Diarrhea | - | - |
Odevixibat | Phase 3 | Alagille Syndrome | - | - |
Botulinum toxin type A | Phase 3 | Cervical Dystonia | - | - |
Lanreotide autogel 120 mg | Phase 2 | Pancreatic Tumours | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ipsen S.A.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in Ipsen S.A.'s (IPN.PA) pipeline across Phase 3, Phase 2. Its lead program is Smecta (Diosmectite), duration of treatment - 7 days (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ipsen S.A.'s next FDA catalyst?→
Ipsen S.A.'s (IPN.PA) next tracked catalyst is a Phase 2 expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IPN.PA biotech catalysts?→
Add IPN.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ipsen S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.